Angitia Biopharmaceuticals Secures $120 Million in Series C Funding to Develop Novel Musculoskeletal Treatments

Angitia Biopharmaceuticals, Series C funding, Musculoskeletal diseases, Osteoporosis, Osteogenesis imperfecta (OI), Spinal fusion, Bispecific antibodies, Clinical development

Nabla Bio Revolutionizes AI-Driven Protein Design with $26M Series A Funding and Major Pharmaceutical Collaborations

Generative Protein Design, AI-Driven Drug Development, Therapeutic Antibodies, Multipass Membrane Proteins, Pharmaceutical Collaborations, Series A Funding